Pharmacoeconomic Studies For Saudi Arabia

Evidence-Based Value. Market Access Support.

Unlock the full value of your product with robust evidenceGet in touch

Baupharma provides comprehensive pharmacoeconomics evaluations to support evidence-based decision-making in healthcare. By integrating clinical outcomes with economic data, Baupharma helps clients demonstrate the value of their products, optimize resource allocation, and support pricing, reimbursement, and market access strategies.

Our services are tailored to meet local and global regulatory and payer requirements. Services include:

Cost-effectiveness analysis (CEA)
Cost-utility analysis (CUA)
Cost-minimization analysis (CMA)
Cost-benefit analysis (CBA)
Budget impact analysis (BIA)

A pioneer in the Saudi Market,Baupharma delivered the first full pharmacoeconomic study in Saudi Arabia

Our team ensures robust methodologies, transparent assumptions, and high-quality deliverables aligned with international guidelines.

Pharmacoeconomic study for the Saudi market

Partial or Full EES?

Understanding which approach fits your product begins with the nature of the economic evaluation required:

Partial Economic Studies

It is a sub-discipline of economic evaluation where an analysis of cost or consequence occurred independently e.g.:

Budget Impact Analysis (BIA)

Full Economic Studies / PES

It is a sub-discipline of economic evaluation where an analysis of different intervention compared in terms of both their costs and their added value for an outcome. There are four main types of PESs:

CEACMACUACBA

Partial Economic Studies

Budget Impact Analysis (BIA)

An economic evaluation that assess the financial impact of the adoption of new intervention that can aid in setting and allocating resources relative to its affordability.

Full Economic Studies or Pharmacoeconomics Evaluation Studies (PES)

Cost Effectiveness Analysis (CEA)

Is a comparative economic evaluation of two or more alternatives intervention in terms of their relative costs and outcomes, where the later are measured in a natural unit.

Cost Utility Analysis (CUA)

Is a comparative economic evaluation where the outcomes are expressed by a using either generic preference-based measure or condition specific-based measure that considers both the effect on mortality and morbidity.

Cost Minimization Analysis (CMA)

Is a comparative economic evaluation in which the outcomes of the two or more comparators are assumed to have equivalent health effects.

Cost Benefit Analysis (CBA)

Is a comparative economic evaluation, where both the costs and outcomes are expressed in monetary terms.

Our approach emphasizes transparency, methodological rigor, and compliance with international guidelines and best practices. Baupharma works closely with clients to customize each study, ensuring alignment with strategic objectives and local market access requirements.